Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific production - Institute for Cancer Research
Annual report 2015 (pdf format)
Molecular targeting of tumor hypoxia is a promising strategy for improving the radiotherapy of cervical cancer. A biomarker for classifying patients according to hypoxia is, however, lacking and is an important requirement for reliable drug evaluation and to avoid added toxicity to patients with no expected benefit.
In a study published in Clinical Cancer Research (journal impact factor 8.7), postdoc Christina S. Fjeldbo (photo) in Lyng’s group and colleagues at Oslo University Hospital and Aarhus University Hospital present a hypoxia classifier that is reflected in diagnostic DCE-MR images and based on the expression level of six genes in a biopsy.
The Norwegian Cancer Genomics Consortium participates in international study of gene variants predisposing for cancer development.
Norwegian Cancer Genomics Consortium (NCGC) consists of clinicians and specialised cancer research groups, situated at the Norwegian University Hospitals, and is led by professor Ola Myklebost (photo) from the Department of Tumor Biology at Oslo University Hospital.
The NCGC participates in an international study of gene variants predisposing for cancer development. Findings from the study has recently been published in Lancet Oncology (journal impact factor 24.69). The article - entitled "Monogenic and polygenic determinants of sarcoma risk: an international genetic study" has also got an editorial comment: "Are sarcomas hereditary?".
The Norwegian Cancer Society calls attention to collaborative study on relevance of genetic heterogeneity
The Norwegian Cancer Society has recently presented a research project on their home page where researchers from Oslo and Bergen have performed genetic analyses on cancer cells that have spread from the gut to the liver. The results show that the degree of genetic heterogenenity between the metastases to the liver may reveal important prognostic information.. The study led by Ragnhild A. Lothe from the Department of Moleceular Oncology at OUS and Per Eystein Lønning from Haukeland University Hospital.
Clinical relevance of genetic heterogeneity among distinct liver metastatic deposits identified in patients with colorectal cancer
In this collaborative study with Dept Oncology, Haukeland University Hospital and Dept Computer Science, University of Oslo, scientist Anita Sveen (photo) and colleagues in the Lothe group show that patients with a low level of heterogeneity, based on DNA copy number analyses of multiple metastases per patient, have a 4.6X and 3.6X longer three-year progression free and overall survival rate than patients with a high heterogeneity level.
Marina Vietri from Institute for Cancer Research and Centre for Cancer Biomedicine is awarded H.M. the King's Gold Medal for best thesis of the Faculty of Medicine.
She will receive the medal at the annual celebration of the University of Oslo in the University Aula on 2nd September.
The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2017.
The total funding available for this call is approximately 100 million Norwegian kroner.
Application deadline is Tuesday, September 6th 2016 kl. 16:00.
Aug 23, 2016
Aug 22, 2016
Aug 11, 2016
Aug 11, 2016
Inst. for Cancer Research
microRNAs as cancer biomarkers
Scand J Clin Lab Invest Suppl, 245, S80-3
Tumour hypoxia causes DNA hypermethylation by reducing TET activity
Nature (in press)
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
The genomic landscape of pancreatic and periampullary adenocarcinoma
Cancer Res (in press)